Revisiting TSCPC as an option

Article

Procedure has ability to lower IOP, preserve vision similar to trabeculectomy and tube shunts

Blebless ab externo glaucoma surgeries, which include canaloplasty and deep sclerectomy, are successful at lowering high IOP while still maintaining a good safety profile. Filtering surgeries, such as trabeculectomy, ExPRESS shunt (Alcon Laboratories, Fort Worth, Texas, USA), and tubes, are the go-to options when a patient requires an IOP lower than 10 to 12 mmHg.

Transscleral cyclophotocoagulation (TSCPC) has typically been reserved for patients with little hope of maintaining their vision. The American Academy of Ophthalmology Ophthalmic Technology Assessment Committee stated, "Cyclophotocoagulation is indicated for patients with refractory glaucoma who have failed trabeculectomy or tube shunt procedures, patients with minimal useful vision and elevated IOP, patients who have no visual potential and need pain relief, and patients with complicated glaucoma and conjunctival scarring from previous surgery."1

New techniques, such as the slow coagulation method by Doug Gaasterland, are making TSCPC safer. This approach uses a lower amount of energy over a longer duration of time, leaving the eyes quieter, and it reduces some of the complications, such as inflammation, uveitis and cystoid macular oedema.

On the cusp of development is a MicroPulse CPC procedure, which is believed will further enhance safety and allow more comfort in using the procedure earlier in the treatment paradigm. In addition, the use of steroids and non-steroidal anti-inflammatory drugs perioperatively has helped mitigate some of the complications.

A glaucoma device (G-Probe, Iridex, Mountain View, California, USA) is designed to direct infrared energy toward the ciliary body and I tend to err on the side of posterior placement as well. In highly myopic eyes, I often use transillumination to identify the exact location of the ciliary body. This technique is effective anytime extra confidence is needed with where to direct the laser and more precise targeting of the ciliary processes can reduce pain and inflammation after the procedure.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.